These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 33597205)
1. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Tummala R; Abreu G; Pineda L; Michaels MA; Kalyani RN; Furie RA; Morand EF Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33597205 [TBL] [Abstract][Full Text] [Related]
2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. Loncharich MF; Anderson CW ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371 [TBL] [Abstract][Full Text] [Related]
3. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Kalunian KC; Furie R; Morand EF; Bruce IN; Manzi S; Tanaka Y; Winthrop K; Hupka I; Zhang LJ; Werther S; Abreu G; Hultquist M; Tummala R; Lindholm C; Al-Mossawi H Arthritis Rheumatol; 2023 Feb; 75(2):253-265. PubMed ID: 36369793 [TBL] [Abstract][Full Text] [Related]
4. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Tanaka Y; Tummala R Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461 [TBL] [Abstract][Full Text] [Related]
5. The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis. Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Kawakami A; Hayashi N; Abreu G; Yavuz S; Lindholm C; Al-Mossawi H; Takeuchi T Mod Rheumatol; 2024 Jul; 34(4):720-731. PubMed ID: 37706527 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study. Chatham WW; Furie R; Saxena A; Brohawn P; Schwetje E; Abreu G; Tummala R Arthritis Rheumatol; 2021 May; 73(5):816-825. PubMed ID: 33225631 [TBL] [Abstract][Full Text] [Related]
7. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R; Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377 [TBL] [Abstract][Full Text] [Related]
8. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. Bruce IN; van Vollenhoven RF; Psachoulia K; Lindholm C; Maho E; Tummala R Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36639192 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis. Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Hayashi N; Abreu G; Tummala R; Morand EF; Takeuchi T Mod Rheumatol; 2023 Jan; 33(1):134-144. PubMed ID: 35134970 [TBL] [Abstract][Full Text] [Related]
10. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R; N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795 [TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Tanaka Y; Takeuchi T; Okada M; Ishii T; Nakajima H; Kawai S; Nagashima T; Hayashi N; Wang L; Tummala R Mod Rheumatol; 2020 Jan; 30(1):101-108. PubMed ID: 30793642 [No Abstract] [Full Text] [Related]
12. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Chia YL; Zhang J; Tummala R; Rouse T; Furie RA; Morand EF Rheumatology (Oxford); 2022 May; 61(5):1900-1910. PubMed ID: 34528084 [TBL] [Abstract][Full Text] [Related]
13. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Bruce IN; Furie RA; Morand EF; Manzi S; Tanaka Y; Kalunian KC; Merrill JT; Puzio P; Maho E; Kleoudis C; Albulescu M; Hultquist M; Tummala R Ann Rheum Dis; 2022 Jul; 81(7):962-969. PubMed ID: 35580976 [TBL] [Abstract][Full Text] [Related]
14. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Liu Z; Cheng R; Liu Y Front Immunol; 2022; 13():996662. PubMed ID: 36211347 [TBL] [Abstract][Full Text] [Related]
16. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Furie R; Morand EF; Askanase AD; Vital EM; Merrill JT; Kalyani RN; Abreu G; Pineda L; Tummala R Lupus; 2021 Jul; 30(8):1254-1263. PubMed ID: 33977796 [TBL] [Abstract][Full Text] [Related]
18. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus. Gensous N; Lazaro E; Blanco P; Richez C Expert Rev Clin Immunol; 2024; 20(1):21-30. PubMed ID: 37800604 [TBL] [Abstract][Full Text] [Related]
19. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Felten R; Scher F; Sagez F; Chasset F; Arnaud L Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735 [TBL] [Abstract][Full Text] [Related]
20. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]